ArticleIJID regions2025
Monitoring methicillin-resistant
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prevalence, Antimicrobial Resistance Profile, and Multidrug Resistance of Methicillin-ResistantHealth science reports · 2026Article
- Temporal Trends in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Inhibitory activity of silver nanoparticles on Staphylococcus aureus growth and α-hemolysin gene expression.Molecular biology reports · 2026Article
- Bacteriophages as Therapeutic Agents for Pulmonary Infections: From Biological Principles to Clinical Applications.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Methicillin-resistant Methods: This retrospective study analyzed clinical specimens tested for Results: A total of 1,824 Conclusion: MRSA prevalence fluctuated over the 3-year period, with a temporary decline in 2023 followed by a rebound in 2024. These findings underscore the importance of continuous surveillance and adaptable infection control strategies to address evolving antimicrobial resistance in hospital environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.